Johnson & Johnson (JNJ)vsInsulet Corporation (PODD)
JNJ
Johnson & Johnson
$271.17
+0.86%
HEALTHCARE · Cap: $615.87B
PODD
Insulet Corporation
$148.93
-0.60%
HEALTHCARE · Cap: $9.79B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 3153% more annual revenue ($99.33B vs $3.05B). JNJ leads profitability with a 16.2% profit margin vs 12.3%. JNJ appears more attractively valued with a PEG of 2.82. PODD earns a higher WallStSmart Score of 65/100 (C+).
JNJ
Buy57
out of 100
Grade: C
PODD
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-83.0%
Fair Value
$144.12
Current Price
$271.17
$127.05 premium
Intrinsic value data unavailable for PODD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 25.1%
Generating 6.4B in free cash flow
Earnings expanding 328.6% YoY
Every $100 of equity generates 23 in profit
Revenue surging 23.5% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 96.0%
Moderate valuation
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.1%.
Bull Case : PODD
The strongest argument for PODD centers on EPS Growth, Return on Equity, Revenue Growth. Revenue growth of 23.5% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Bear Case : PODD
The primary concerns for PODD are P/E Ratio, PEG Ratio.
Key Dynamics to Monitor
JNJ profiles as a mature stock while PODD is a growth play — different risk/reward profiles.
PODD carries more volatility with a beta of 1.10 — expect wider price swings.
PODD is growing revenue faster at 23.5% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
PODD scores higher overall (65/100 vs 57/100) and 23.5% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Insulet Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company is headquartered in Acton, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?